NeuroPace’s stock has delivered impressive returns, with a year-to-date price increase of over 46%, according to InvestingPro data. Despite this strong performance, the company is currently trading at ...
-- Submission supported by positive preliminary 18-month NAUTILUS data in patients with drug-resistant idiopathic generalized epilepsy (IGE) and generalized tonic-clonic (GTC) seizures -- The PMA-S is ...
Investing.com - NeuroPace Inc (NASDAQ:NPCE) shares traded higher Monday following the announcement of positive 18-month results from its NAUTILUS clinical trial, which evaluated the company’s RNS ...
-- Submission supported by positive preliminary 18-month NAUTILUS data in patients with drug-resistant idiopathic generalized epilepsy (IGE) and generalized tonic-clonic (GTC) seizures -- NeuroPace, ...
Hosted on MSN
UBS maintains NeuroPace (NPCE) buy recommendation
Fintel reports that on December 16, 2025, UBS maintained coverage of NeuroPace (NasdaqGM:NPCE) with a Buy recommendation. Analyst Price Forecast Suggests 12.12% Upside As of December 6, 2025, the ...
MOUNTAIN VIEW, Calif., December 08, 2025--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, announced the ...
As of December 6, 2025, the average one-year price target for NeuroPace is $17.85/share. The forecasts range from a low of $15.15 to a high of $21.00. The average price target represents an increase ...
People with drug-resistant epilepsy have had few other options, but Neuropace Inc. appears on target to provide an alternative. The Nautilus trial of its responsive neurostimulation system for ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback